Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
188
resultados
Última actualización
01/11/2025 [06:57:00]
Resultados 50 a 75 de 188
Resumen de: US2025332116A1
The present invention relates to new carbon-based antiviral nanoparticles, compositions comprising said nanoparticles, materials and devices coated with said nanoparticles, said nanoparticles for medical use, methods for the preparation of said nanoparticles, compositions, materials and devices.
Resumen de: US2025332112A1
Certain embodiments of the invention provide ionizable lipids having optimized clearance properties. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising ionizable lipids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.
Resumen de: US2025332104A1
The present disclosure relates to a dendron-like lipid compound, a liposome, a lipid complex, and a lipid nanoparticle and a use thereof. The dendron-like lipid compound is selected from any one of structures of formulas I-III. The present disclosure relates to a series of dendron-like lipid compounds of novel structures; and liposomes prepared from the lipid compounds have uniform particle size distribution, carry negative charges on the surfaces, and have low cytotoxicity. The lipid nanoparticle can specifically target and deliver active substances to cells, tissues or organs, thereby realizing targeted delivery of the active substances.
Resumen de: US2025332103A1
The present disclosure relates to a method for manufacturing a nanobubble-based drug delivery vehicle using a circle type focused ultrasonic technology, and a nanobubble-based drug delivery vehicle manufactured thereby, and more specifically, to a method for manufacturing a drug delivery vehicle using a circle type focused ultrasonic technology, the drug delivery vehicle including a shell, and a drug and nanobubbles contained inside the shell, and a nanobubble-based drug delivery vehicle manufactured thereby.
Resumen de: AU2024273170A1
Disclosed are methods for treating muscle wasting diseases, such as spinal muscular atrophy, or muscular dystrophies, using matrix bound vesicles (MBV). Compositions for use in treating a muscle wasting disease are also disclosed.
Resumen de: AU2023440872A1
The present invention provides an amino lipid, and lipid nanoparticles (LNPs) and a use thereof, the amino lipid having a structure represented by general formula (I), or an isomer, pharmaceutically acceptable salt, prodrug or solvate of the amino lipid. The present invention further provides LNPs containing the amino lipid. According to the present invention, the amino lipid having a structure represented by general formula (I) is used as an ionizable lipid compound, and the LNPs are obtained by means of self-assembly of the ionizable lipid compound, a steroid, a neutral lipid, and a polymer-bonded lipid. The LNPs can further improve the translation expression level of a nucleic acid load in cells, improve the effect of a nucleic acid-LNP preparation, and enable the nucleic acid-LNP preparation to provide a theoretical basis for personalized treatment.
Resumen de: WO2025226878A2
Provided herein are compositions and methods to protect cargo DNA when it is loaded into lipid nanoparticles (LNPs) or similar nanocarrier systems. In certain embodiments, the compositions include a lipid nanoparticle (LNP) that includes a DNA cargo and a molecule capable of condensing and/or compacting DNA. In certain embodiments, the compositions also include a "helper molecule" that provides reduced inflammatory response and reduced DNA degradation by DNAse enzymes and autophagy/xenophagy during and after endosomal escape, upon administration.
Resumen de: WO2024137953A2
This disclosure relates to Snu13 polypeptides and polynucleotides (e.g., mRNA) encoding the same for use in translational control of a second polynucleotide (e.g., target mRNA). mRNA therapies of the disclosure express Snu13 polypeptides, which control the translation of a target polynucleotide comprising a Snu13-binding site. Thus, the disclosure also features compositions or systems and uses thereof, comprising a first polynucleotide encoding a target molecule and comprising a Snu13-binding site and a second polynucleotide encoding a Snu13 polypeptide. The disclosure also relates to delivery agents (e.g., lipid nanoparticles) and compositions comprising the Snu13 polynucleotides (e.g., mRNAs) of the disclosure.
Resumen de: TW202438044A
A compound having the following structure of Formula (I): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, R4, R5, R6, G1, G2, x, y, n, z, and w are as defined herein. Compositions comprising the compounds, and their use in methods of treating diseases, are also described.
Resumen de: MX2025007398A
The present invention provides, in part, bis-ester and amide cationic lipid compounds of Formula (I):, or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (II):, or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (III):, or a pharmaceutically acceptable salt thereof, and bis-ester and amide cationic lipid compounds of Formula (IV):, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Resumen de: WO2024133892A1
A crosslinked vesicle comprising an outer layer and an inner core, said outer layer comprising a cationic amphiphilic peptide and said inner core comprising a fluorinated compound in liquid form, wherein said cationic amphiphilic peptide is a compound of formula (I) HB - CL - HP (I), wherein HB is a fluorinated hydrophobic block, CL is a cross-linking motif, HP is a cationic hydrophilic amino acid sequence having an alpha-helix structure and comprising at least (1) positive charge and said vesicle has a zeta potential of at least (20) mV.
Resumen de: CN120475964A
There is provided a composition comprising: (a) an active ingredient; and (b) a lipid mixture comprising: (i) a cationically ionizable lipid capable of forming lipid nanoparticles; (ii) a steroid; and (iii) a negatively charged amphiphile having a hydrophilic portion and a lipophilic portion; wherein the composition is a lipid nanoparticle composition and is substantially free of a polyethylene glycol conjugated lipid wherein the polyethylene glycol (PEG) moiety of the PEG conjugated lipid has at least 5 contiguous ethylene glycol repeat units.
Resumen de: MX2025006743A
The present invention pertains to a composition comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of nucleic acids in the lipid bilayer. The present invention furthermore pertains to said composition, for use in preventing and/or treating a disease, in particular for use in preventing and/or treating cancer. The present invention furthermore pertains to a method for producing a composition comprising said nucleic acid-lipids particles.
Resumen de: AU2023410864A1
The invention provides a composition, e.g., in the form of a powder, comprising chitosan particles. The invention also provides method for treating an oral condition in a patient by administering to the patient a composition of the invention to treat the oral condition. The invention further provides devices suitable for administering the composition.
Resumen de: MX2025007204A
Aspects of the present disclosure provides for improved mycobacterium tuberculosis vaccine compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl - dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Other aspects of the present disclosure provide mRNA that encodes for concatenated peptides encoding for multiple MHC-II tuberculosis epitopes, and optionally includes a second mRNA encoding for concatenated MHC-I tuberculosis epitopes.
Resumen de: WO2024137831A2
A composition of bacteriophages comprising at least one phage selected from TTS1, TTS2, TTS3, TTS4, TTS5, and TTS6, wherein the phages are optionally encapsulated; and a method for preventing or treating an infection caused by Salmonella Gallinarum by administering to a subject a therapeutically effective amount of the composition.
Resumen de: WO2024137579A2
The present disclosure relates to compositions, systems, and methods for modulating immune cell responses in a subject. In particular, the disclosure provides membrane-coated nanoparticles comprising a nanoparticle shell coated with a cell membrane obtained from an antigen presenting cell, and methods of use thereof to modulate an immune response in a sample or a subject.
Resumen de: EP4640669A1
The present invention provides a cycloalkane-based lipid compound of Formula 1 and a pharmaceutically acceptable salt thereof. The cycloalkane-based lipid compound is a compound having a form in which carbonyl-based substituents are bonded to the central structure of a cycloalkane. The cycloalkane-based lipid compound according to the present invention is used as an ionizable lipid, which is a component of a lipid nanoparticle for delivering a nucleic acid.
Resumen de: MX2025006766A
The present invention relates to a novel ionizable lipid compound represented by formula (I) or a salt thereof, and lipid nanoparticles including the same. Lipid nanoparticles including a novel ionizable lipid compound according to the present invention have excellent nucleic acid encapsulation efficiency and high cell delivery efficiency of nucleic acids.
Resumen de: US2025319037A1
The object of the present invention is to provide a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells which can realize excellent delivery efficiency to organs other than the liver, and a composition containing a therapeutic agent and lipid nanoparticles which can realize excellent delivery efficiency to an organ other than the liver. The present invention provides a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells, which comprises administering a lipid composition to a subject, wherein the lipid composition comprises the therapeutic agent and lipid nanoparticle,and wherein the lipid nanoparticle comprises an ionizable lipid and a compound represented by formula (1) or a salt thereof.wherein G1 represents —C(O)—, —OC(O)—, —O(CO)O— or —C(O)O—,LY represents a single bond, an alkylene group having 1-14 carbon atoms, a substituted alkylene group having 1-14 carbon atoms, a heteroalkylene group having 1-14 carbon atoms, and a substituted heteroalkylene group having 1-14 carbon atoms.X represents a basic functional group.
Resumen de: AU2023409836A1
The present disclosure relates compositions of RNA encapsulated in lipid nanoparticles and methods of producing the same The compositions can be used for delivery of mRNA to a subject. The lipid nanoparticles have improved properties for delivery of biologically active agents, such as RNA.
Resumen de: AU2023409835A1
The present disclosure provides lipid nanoparticles having a sphere like structure, compositions comprising the lipid nanoparticles and methods for delivery of the agents. The lipid nanoparticles have improved properties for delivery of biologically active agents, such as RNA.
Resumen de: WO2024134220A1
The present invention provides a cup-shaped particle comprising a first polymer and a second polymer; wherein the first polymer is a biodegradable polymer; the second polymer is a crosslinked copolymer of two or more different methacrylate monomers and at least one crosslinking agent, wherein the at least one cross-linking agent comprises one or more dimethacrylates; and wherein the cup has a cavity having an opening of at least 50 nm in size.
Resumen de: CN120569190A
The invention relates to a method for preparing stable nanoparticles and a pharmaceutical composition thereof. In addition, the nanoparticles prepared by the method have stable and controllable average particle size and particle size distribution.
Nº publicación: EP4637718A1 29/10/2025
Solicitante:
SUZHOU ABOGEN BIOSCIENCES CO LTD [CN]
Suzhou Abogen Biosciences Co., Ltd
Resumen de: CN119095585A
An LNP comprising a phospholipid comprising a sterol moiety is provided. The LNP containing the phospholipid has potential application in the mRNA vaccine technology. Compositions comprising the LNPs and methods of using the LNPs or the compositions as described above are provided.
BOPI
Sede Electrónica
